Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Candel Therapeutics, Inc. (CADL : NSDQ)
 
 • Company Description   
Candel Therapeutics Inc. is a late clinical stage biopharmaceutical company. It involved in developing novel oncolytic viral immunotherapies. The company's product pipeline includes CAN-2409 and CAN-3110. Candel Therapeutics Inc. is based in NEEDHAM, Mass.

Number of Employees: 65

 
 • Price / Volume Information   
Yesterday's Closing Price: $4.00 Daily Weekly Monthly
20 Day Moving Average: 95,369 shares
Shares Outstanding: 28.69 (millions)
Market Capitalization: $114.77 (millions)
Beta:
52 Week High: $14.78
52 Week Low: $3.33
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -22.93% -15.87%
12 Week -4.99% 2.69%
Year To Date -48.85% -39.41%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
117 KENDRICK STREET SUITE 450
-
NEEDHAM,MA 02494
USA
ph: 617-916-5445
fax: -
investors@candeltx.com http://www.candeltx.com
 
 • General Corporate Information   
Officers
Paul Peter Tak - President and Chief Executive Officer
Paul B Manning - Chairman
John Canepa - Chief Financial Officer
Edward J. Benz Jr - Director
Chris Martell - Director

Peer Information
Candel Therapeutics, Inc. (CORR.)
Candel Therapeutics, Inc. (RSPI)
Candel Therapeutics, Inc. (CGXP)
Candel Therapeutics, Inc. (BGEN)
Candel Therapeutics, Inc. (GTBP)
Candel Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 137404109
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 09/14/22
Share - Related Items
Shares Outstanding: 28.69
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $114.77 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.48 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.91 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 09/14/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.80
Price/Cash Flow: -
Price / Sales: 925.58
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -160.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 0.00%
ROE
03/31/22 - -29.17
12/31/21 - -68.49
09/30/21 - -
ROA
03/31/22 - -13.57
12/31/21 - -26.63
09/30/21 - -
Current Ratio
03/31/22 - 17.48
12/31/21 - 15.84
09/30/21 - 20.68
Quick Ratio
03/31/22 - 17.48
12/31/21 - 15.84
09/30/21 - 20.68
Operating Margin
03/31/22 - -
12/31/21 - -11,591.94
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -29,132.26
09/30/21 - -
Pre-Tax Margin
03/31/22 - -34,967.74
12/31/21 - -28,899.20
09/30/21 - -
Book Value
03/31/22 - 2.22
12/31/21 - 2.24
09/30/21 - 2.20
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.32
12/31/21 - 0.01
09/30/21 - 0.01
Debt-to-Capital
03/31/22 - 24.35
12/31/21 - 0.87
09/30/21 - 0.85
 

Powered by Zacks Investment Research ©